
    
      A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity, Safety,
      Tolerability, and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate
      Cancer (mCRPC) (PYRUS)
    
  